Aegis Affirms Progenics Pharma (PGNX) at 'Buy'; Solid Relistor Results Fuel Q3 Revenue Gains (VRX)

November 8, 2016 11:57 AM EST
Get Alerts PGNX Hot Sheet
Price: $8.87 +3.62%

Rating Summary:
    5 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 18 | New: 19
Trade PGNX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Aegis Capital affirms Progenics Pharma (Nasdaq: PGNX) at Buy with a price target of $11 following Q3 results issued on Monday

3Q revenues were driven by the approval (which triggered a $50 million milestone by Valeant Pharmaceuticals) and US launch of oral Relistor for OIC in adults with chronic non-cancer pain in July and September, respectively. Progenics received $3.3 million in Relistor royalties from $22.1 million in Valeant sales of Relistor (oral and SUBQ). Progenics also announced a Relistor royalty-based loan that has brought PGNX cash to $98.9 million, which we expect will allow PGNX to fund Azedra to initial commercialization and develop its prostate assets through 2018. PGNX continues to expect Azedra top-line data in 1H17, and we view the trial as substantially de-risked and expect a late 2017 approval due to Breakthrough Designation status, which would make Azedra the first approved treatment for malignant or recurrent pheochromocytoma and paraganglioma in the US – we believe Azedra represents about a $150 million market opportunity.

For an analyst ratings summary and ratings history on Progenics Pharmaceuticals click here. For more ratings news on Progenics Pharmaceuticals click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS View

Add Your Comment